Jay Brenman, PhD
Education and Training
B.S., University of California at Berkeley, 1992
Ph.D., University of California at San Francisco, 1997
Areas of Interest
All cells and organisms must monitor and maintain their energy levels for survival. One particular protein kinase, AMP-activated protein kinase (AMPK) plays a central role in energy balance and metabolism. AMPK consists of a protein complex encoded by three subunits, a serine-threonine kinase catalytic subunit (α) and two regulatory subunits (ß, γ). When AMPK signaling is disrupted cells undergo cell death under stressors and organisms can not survive limited starvation.
AMPK has many potential biomedically-relevant functions. AMPK is proposed to be a therapeutic target for Type 2 diabetes and Metabolic syndrome (obesity, insulin resistance, cardiovascular disease). In addition, since cancer cells have larger energetic requirements than non-dividing cells, targeting AMPK might be an attractive approach for attacking cancer as an additive therapy.
We identified mutations in the AMPK kinase domain (AMPKα) during a genetic screen looking for "neurodegeneration mutants" in Drosophila. Inactivation of AMPK leads to neurodegeneration-like phenotypes in neurons and abnormal metabolism in other cells. Our lab uses combinations of mouse and fruitfly genetics, biochemistry/proteomics and cell culture models to try to further identify new molecules involved in AMPK signaling. We are particularly interested in how AMPK signaling and molecules it regulates are relevant to:
- Metabolism (Type 2 Diabetes/fatty liver)
- and Cancer
Many of our studies use Drosophila melanogaster (the fruit fly) due to the powerful genetics of this assay system and conserved molecules in AMPK signaling. However, we also use mouse genetics to explore AMPK function in two contexts: 1) In brains of knockout mice to explore the role of AMPK signaling in normal function; and 2) In brain tumor cancer models.
Other studies use differential proteomics (in collaboration with Dr. Ben Major) in combination with AMPK knockout cells and tissues to elaborate new AMPK signaling targets/components.
We have also more recently begun to use a mouse knockout model for studying carbonic anhydrase-3 (Car3), which is expressed predominantly in tissues that utilize/make fats (adipose, slow twitch muscle, and fatty liver) and exquisitely regulated by nutritive state. We believe Car3 will be an important biomarker and molecular enzyme relevant to obesity and metabolic syndrome.
A joint project (with Dr. J. Sexton, NCCU) involves developing new cell based assays and identifying new biomarkers for new compounds that could become therapeutics for metabolic diseases (particularly Type 2 Diabetes and fatty liver).